The Use of Biomarkers in Early-Stage NSCLC

H&O Should patients with early-stage non–small cell lung cancer (NSCLC) get biomarker testing of their surgical specimens? JK A few years ago, I would have said […]

Neoadjuvant and Adjuvant Approaches in Surgically Resectable NSCLC

H&O Which patients with non–small cell lung cancer (NSCLC) are eligible for surgical resection? JC Surgical resectability, which is determined by the thoracic surgeon, is based […]

Hem/Onc News

Tisotumab Vedotin-tftv Approved for Recurrent or Metastatic Cervical Cancer On September 20, the US Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tivdak, […]

Stereotactic Body Radiation Therapy in Advanced NSCLC

H&O What is the standard first-line treatment in advanced non–small cell lung cancer (NSCLC)? TW The standard treatment for unresectable, locally advanced stage III NSCLC is […]

Emerging Role of Immunotherapy in Locally Advanced Non–Small Cell Lung Cancer

Abstract: Non–small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC […]

Hem/Onc News

Duvelisib Approved in Relapsed/Refractory CLL, SLL, and FL The US Food and Drug Administration (FDA) approved duvelisib (Copiktra, Verastem) on September 24 for adults with relapsed […]

Hem/Onc News

Pembrolizumab Receives Regular Approval in Metastatic Nonsquamous NSCLC On August 20, the US Food and Drug Administration (FDA) granted regular approval to pembrolizumab (Keytruda, Merck) for […]

Hem/Onc News

Apalutamide Approved for Use in Nonmetastatic Castration-Resistant Prostate Cancer The US Food and Drug Administration (FDA) on February 14 approved the next-generation androgen receptor inhibitor apalutamide […]

ALK Inhibitors in Non–Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?

H&O Which patients with non–small cell lung cancer (NSCLC) are candidates for treatment with crizotinib? AS Crizotinib (Xalkori, Pfizer) is a multitargeted tyrosine kinase inhibitor […]

Hem/Onc News

Abemaciclib Approved in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer On September 28, the US Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Lilly) as a […]